ATE517179T1 - Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür - Google Patents

Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür

Info

Publication number
ATE517179T1
ATE517179T1 AT02753754T AT02753754T ATE517179T1 AT E517179 T1 ATE517179 T1 AT E517179T1 AT 02753754 T AT02753754 T AT 02753754T AT 02753754 T AT02753754 T AT 02753754T AT E517179 T1 ATE517179 T1 AT E517179T1
Authority
AT
Austria
Prior art keywords
cryptovirus
disclosed
methods
nucleic acids
isolated
Prior art date
Application number
AT02753754T
Other languages
German (de)
English (en)
Inventor
Steven Robbins
Original Assignee
Cryptic Afflictions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cryptic Afflictions Llc filed Critical Cryptic Afflictions Llc
Application granted granted Critical
Publication of ATE517179T1 publication Critical patent/ATE517179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
AT02753754T 2001-02-07 2002-02-07 Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür ATE517179T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26725301P 2001-02-07 2001-02-07
PCT/US2002/004117 WO2002077211A2 (en) 2001-02-07 2002-02-07 A virus (cryptovirus) within the rubulavirus genus and uses therefor

Publications (1)

Publication Number Publication Date
ATE517179T1 true ATE517179T1 (de) 2011-08-15

Family

ID=23017976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753754T ATE517179T1 (de) 2001-02-07 2002-02-07 Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür

Country Status (6)

Country Link
EP (1) EP1373477B1 (cg-RX-API-DMAC7.html)
JP (1) JP4324379B2 (cg-RX-API-DMAC7.html)
AT (1) ATE517179T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002306472C1 (cg-RX-API-DMAC7.html)
CA (1) CA2436208C (cg-RX-API-DMAC7.html)
WO (1) WO2002077211A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
FR2938840B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
FR2938841B1 (fr) * 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
WO2011150320A2 (en) * 2010-05-27 2011-12-01 University Of Georgia Research Foundation, Inc. Activators of innate immunity
CN113481185B (zh) * 2021-08-05 2022-12-02 云南师范大学 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用
WO2025076466A2 (en) * 2023-10-06 2025-04-10 Cyanvac Llc Piv5-based vaccines with modified antigen: methods of making and using the same

Also Published As

Publication number Publication date
JP2005503766A (ja) 2005-02-10
CA2436208A1 (en) 2002-10-03
CA2436208C (en) 2014-04-15
EP1373477B1 (en) 2011-07-20
AU2002306472B2 (en) 2008-03-06
WO2002077211A3 (en) 2003-10-16
EP1373477A2 (en) 2004-01-02
WO2002077211A8 (en) 2002-11-21
AU2008202524A1 (en) 2008-06-26
JP4324379B2 (ja) 2009-09-02
WO2002077211A2 (en) 2002-10-03
AU2002306472C1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
Cayrol IL-33, an alarmin of the IL-1 family involved in allergic and non allergic inflammation: focus on the mechanisms of regulation of its activity
Luan et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated ConA-induced hepatitis
Strutt et al. Multipronged CD 4+ T‐cell effector and memory responses cooperate to provide potent immunity against respiratory virus
Dobrovolskaia et al. Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles
US8334101B2 (en) Intracellular DNA receptor
JP5308161B2 (ja) 損傷組織の機能的再生促進医薬
Palomino-Segura et al. Protection against influenza infection requires early recognition by inflammatory dendritic cells through C-type lectin receptor SIGN-R1
Zhang et al. Potential therapeutic value of the STING inhibitors
Udby et al. Cysteine-rich secretory protein 3 is a ligand of α1B-glycoprotein in human plasma
RU2546249C2 (ru) Композиция для усиления экспрессии трансгена в эукариотических клетках и способ увеличения продукции целевого белка, кодируемого трансгеном
Kierstead et al. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells
CN109239334A (zh) 建立时间分辨荧光免疫层析法检测MxA试剂盒
Seedhom et al. Protein translation activity: a new measure of host immune cell activation
TW201927813A (zh) 用於治療及／或預防異位性皮膚炎之ｉｌ－３１胜肽免疫原及其劑型
ATE517179T1 (de) Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür
Lučiūnaitė et al. Activation of NLRP3 inflammasome by virus-like particles of human polyomaviruses in macrophages
Cheng et al. Transgenic expression of human C-type lectin protein CLEC18A reduces dengue virus type 2 infectivity in Aedes aegypti
Sebastião et al. CuMV VLPs containing the RBM from SARS-CoV-2 spike protein drive dendritic cell activation and Th1 polarization
US20070072172A1 (en) Liver specific chimeric regulatory sequence and use thereof
Nishihara et al. Enhanced cellular uptake of CpG DNA by α-helical antimicrobial peptide Kn2-7: Effects on macrophage responsiveness to CpG DNA
Boulaire et al. Gene expression profiling to define host response to baculoviral transduction in the brain
Jose et al. Isolation and characterization of primary microglia from post‐natal murine brain tissues: a comparison of two methods
KR100801810B1 (ko) 슈퍼-항원 융합 단백질들 및 그 용도
Zhang et al. PLZF-expressing CD4+ T cells promote tissue-resident memory T cells in breaking immune tolerance in allergic asthma via IL-15/IL-15Rα signaling
Chen et al. An Intein-Spliced Nipah G Protein Ferritin Nanoparticle Vaccine Provides Complete Protection against Lethal Nipah Virus Challenge

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties